Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-TechneMEX:TECH 88 EV-to-EBIT is 42.37 as of Aug. 16, 2026, which is 12% below its 10-year median of 47.90. GuruFocus rates MEX:TECH with a GF Score™ of 88/100 and a GF Value™ of MXN1,068.47. The stock has 7 warning signs investors should review. Among 370 Biotechnology companies, Bio-Techne ranks worse than 78.65% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bio-Techne's Enterprise Value for the quarter that ended in Jun. 2026 was MXN170,259 Mil.
Bio-Techne's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN4,545 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne EV-to-EBIT Related Terms
Bio-Techne EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bio-Techne's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs CYTK, SMMT, BMRN: EV-to-EBIT Comparison
For the Biotechnology subindustry, Bio-Techne's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bio-Techne's EV-to-EBIT falls into.
Bio-Techne's current Enterprise Value is MXN192,581 Mil.
Bio-Techne's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN4,545 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (MEX:TECH) has a EV-to-EBIT of 42.37 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio-Techne and its competitors. This is 12% below median its historical median of 47.90. Over the past decade, Bio-Techne's EV-to-EBIT has ranged from 26.13 to 137.55. According to the industry distribution chart, Bio-Techne ranks #291 out of 370 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Bio-Techne's EV-to-EBIT too high?
Bio-Techne's current EV-to-EBIT of 42.37 is 12% below median its 10-year median of 47.90. Over the past 10 years, this metric has ranged from a low of 26.13 to a high of 137.55. The Biotechnology industry median EV-to-EBIT is 16.25. Bio-Techne's value of 42.37 is 160.8% above this industry median. Based on the distribution chart, Bio-Techne ranks #291 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bio-Techne has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's EV-to-EBIT compare to CYTK and SMMT?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #291 out of 370 companies for EV-to-EBIT. This places Bio-Techne in the lower half of its industry. The industry median EV-to-EBIT is 16.25. Bio-Techne's value of 42.37 is 160.8% above this benchmark. Historically, Bio-Techne's own EV-to-EBIT has ranged from 26.13 to 137.55 over the past decade. While the company's 10-year median is 47.90 vs. the industry median of 16.25, Bio-Techne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.25, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current EV-to-EBIT of 42.37 is 160.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current EV-to-EBIT is 42.37, which is 12% below median its own 10-year median of 47.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current EV-to-EBIT of 42.37. The stock's GF Value™ is MXN1,068.47, compared to a current price of MXN1,090.00 — trading 2% above its estimated fair value. The current EV-to-EBIT is 42.37, which is 12% below median its 10-year median of 47.90 and 160.8% above the Biotechnology industry median of 16.25. Bio-Techne's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current EV-to-EBIT is 42.37 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be overvalued.
The current stock price of MXN1,090.00 is trading 2% above its estimated GF Value™ of MXN1,068.47.
Key valuation signals for MEX:TECH:
EV-to-EBIT: 42.37 (12% below median its 10-year median of 47.90)
GF Value™: MXN1,068.47 vs. price of MXN1,090.00 (2% above fair value)
Industry Position: 160.8% above the Biotechnology median (#291 of 370)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
88GF Score
Get the complete analysis for MEX:TECH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
